Last reviewed · How we verify
NCT02131948: Nasal insulin
Regulation of Endogenous Glucose Production by Brain Insulin Action
Phase 1 trial testing Intranasal insulin in Insulin Resistance, Diabetes in 8 participants. Completed in 1 July 2014.
1 July 2014
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 8 |
| Start date | 1 November 2013 |
| Primary completion | 1 July 2014 |
| Estimated completion | 1 July 2014 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Intranasal insulin — full drug profile →
- Intranasal placebo — full drug profile →
Conditions studied
- Insulin Resistance, Diabetes — all drugs for Insulin Resistance, Diabetes →
Sponsor
University Health Network, Toronto
Who can join
Adults 18 to 60, any sex, with Insulin Resistance, Diabetes. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Endogenous glucose production
Time frame: 8 hours
Effects of intranasal insulin and placebo on endogenous glucose production will be assessed
Sponsor's own description
It is well known that the hormone insulin lowers blood glucose in part by acting directly on the liver and reducing hepatic glucose production. Animal studies have shown that the hormone insulin can act on the brain to indirectly lower glucose production by the liver. We aim to test whether this is true in humans by giving insulin intranasally. It has previously been shown that a nasal spray can deliver insulin directly to the brain without affecting circulating insulin concentration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02131948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intranasal insulin
Trials testing the same drug.
- NCT04044534 — Intranasal Insulin for Posttraumatic Stress Disorder · Phase 2 · recruiting
- NCT06072963 — COMMETS- Combination MCI Metabolic Syndrome · Phase 2 · recruiting
- NCT06144255 — Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI) · Phase 1 · completed
- NCT05748990 — Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia · NA · recruiting
- NCT05613491 — Intranasal Insulin Improves Postoperative Neurocognitive Disorders in Elderly Patients · NA · unknown
Other recruiting trials for Insulin Resistance, Diabetes
Currently open trials in the same condition.
- NCT06400082 — Topical Insulin for Postoperative Wound Healing · NA · active not recruiting
- NCT06542718 — Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02131948 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 30 November 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02131948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing